A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of ABY-035 in the Treatment of Subjects With Ankylosing Spondylitis
Latest Information Update: 13 Jul 2023
At a glance
- Drugs Izokibep (Primary)
- Indications Ankylosing spondylitis
- Focus Therapeutic Use
- Sponsors Inmagene
- 21 Sep 2022 Status changed from recruiting to discontinued.
- 07 Mar 2022 Planned primary completion date changed from 31 Oct 2022 to 31 Dec 2022.
- 25 Aug 2021 According to an Affibody media release, Inmagene has received IND approval/clearance in the US, Mainland China, South Korea, and Taiwan for the ASPIRE trial